Announcements Trials
Browse Landscape

Phase

Phase 1 4

Status

Completed 4

Sponsor Class

NIH 4

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 7Dermatologic 5Lymphoid 4Thoracic 3Head & Neck 3Genitourinary 3Sarcoma 2Gynecologic 2Gastrointestinal 2CNS 2Breast 2Myeloid 1

Conditions

Sezary Syndrome 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Leukemia-Lymphoma, Adult T-Cell 1Leukemia, Prolymphocytic, T-Cell 1Carcinoma 1

Interventions

Rituximab 1371Cyclophosphamide 1297Vincristine 662Doxorubicin 583Etoposide 525Prednisone 505Cytarabine 481fludarabine 462Methotrexate 441Dexamethasone 411fludarabine phosphate 396Lenalidomide 347Filgrastim 342Bendamustine Hydrochloride 274Radiotherapy 266venetoclax 255ibrutinib 249Peripheral Blood Stem Cell Transplantation 233Melphalan 229obinutuzumab 228Granulocyte Colony-Stimulating Factor 212Bortezomib 204Gemcitabine 201Busulfan 186Whole-Body Irradiation 185Mycophenolic Acid 174Tacrolimus 164Specimen Handling 161Calcium Dobesilate 150Magnetic Resonance Spectroscopy 149

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Interleukin-15 × Lymphoid × Clear all
NCT01572493 2023-03-06

Continuous Infusion of rhIL-15 for Adults With Advanced Cancer

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
38 enrolled 28 charts
Lymphoid

Carcinoma, Lymphoma

NCT04185220 2023-01-04

Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
6 enrolled 16 charts
LymphoidOther hematologic neoplasm

Mycosis Fungoides, Sezary Syndrome, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT03905135 2022-09-13

Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
8 enrolled 18 charts
DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

NCT02689453 2022-04-29

Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
11 enrolled 16 charts
DermatologicLymphoidOther hematologic neoplasm

Leukemia-Lymphoma, Adult T-Cell, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡